Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04648696 · ClinicalTrials.gov registry record · Phase 4

Safety and Outcomes Associated With Continuous Versus Intermittent Infusion Vancomycin

A Phase 4 study, sponsored by Wake Forest University Health Sciences.

Terminated
Registry status
Phase 4
Development phase
8
Enrollment target

NCT04648696 is a Phase 4 study that was terminated before completion, run by Wake Forest University Health Sciences. The registered enrollment target is 8 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04648696, a Phase 4 study, was terminated before completion, sponsored by Wake Forest University Health Sciences.

TERMINATED
Registry status
Phase 4
Development phase
8 participants
Enrollment target

Study Summary

Evaluate the safety and outcomes associated between the two treatment modalities

Interventions

  • DRUG Vancomycin CI
  • DRUG Vancomycin II

Trial Details

FieldValue
Enrollment Target 8 participants
Start Date 2021-03-03
Est. Completion 2022-10-31
Phase Phase 4

Sponsor

Wake Forest University Health Sciences

1,140 total trials

What the Registry Record Tells You About NCT04648696

The ClinicalTrials.gov registry entry for NCT04648696 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Vancomycin CI is the first listed.

NCT04648696 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04648696 about?

NCT04648696 is a clinical study titled "Safety and Outcomes Associated With Continuous Versus Intermittent Infusion Vancomycin". Evaluate the safety and outcomes associated between the two treatment modalities

What is the current status of trial NCT04648696?

This trial is currently terminated. It is a Phase 4 study. The enrollment target is 8 participants. The study started on 2021-03-03. Estimated completion is 2022-10-31.

What interventions are being tested in trial NCT04648696?

The interventions under investigation include: Vancomycin CI (DRUG), Vancomycin II (DRUG).

Who is sponsoring clinical trial NCT04648696?

This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.